Evidence map›Paper›PMID 40851835›Full record

ArticleAdvanced nanobiomed research2025

Long-Circulating Nanobody Confers Durable Prophylaxis against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Infection.

Geetha Jyothi Vaskuri, Gang Ye, Fan Bu, Dong Yang, Colleen B Jonsson, Hailey Turner-Hubbard, Sydney Winecke, Alise Mendoza, Fang Li, Chalet Tan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced nanobiomed research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Nanobodies targeting SARS-CoV-2 variants.Acta pharmaceutica Sinica. B · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Geetha Jyothi VaskuriDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Gang YeDepartment of Pharmacology, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
Fan BuDepartment of Pharmacology, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
Dong YangRegional Biocontainment Laboratory, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Colleen B JonssonDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA; Regional Biocontainment Laboratory, University of Tennessee Health Science Center, Memphis, TN 38163, USA; Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Hailey Turner-HubbardDepartment of Pharmacology, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
Sydney WineckeDepartment of Pharmacology, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
Alise MendozaDepartment of Pharmacology, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
Fang LiDepartment of Pharmacology, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
Chalet TanDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA.

Funding

Project 5: Pandemic Virus Helicase InhibitorsU19AI171954 · NIAID · UNIVERSITY OF MINNESOTA · PI Reuben S Harris, Fang Li · 2022 to 2026
$100.9M
Facility Management, Maintenance and Operation CoreUC7AI180313 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI ELIZABETH ANN FITZPATRICK · 2023 to 2026
$12.0M
NIAID NIH HHS U19 AI171954NIAID NIH HHS UC7 AI180313
6 · The paper itself

Abstract

Breakthrough infections in vaccinated population and continuous emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants make it imperative to develop more efficacious medical countermeasures. Previously, an anti-SARS-CoV-2 nanobody, Nanosota-3A, that neutralizes the infection of live Omicron BA.1 with picomolar potency, is identified. Herein, Nanosota-3A is fused with the crystallizable fragment (Fc) domain of human IgG1 that contains M252Y/S254T/T256E (YTE) substitutions, named Nanosota-3A-Fc-YTE. Compared to Nanosota-3A-Fc, Nanosota-3A-Fc-YTE exhibits identical binding to the SARS-CoV-2 spike protein yet displays eightfold higher binding affinity for human neonatal Fc receptor (hFcRn) at pH 6.0. In hFcRn transgenic mice, the half-life of Nanosota-3A-Fc and Nanosota-3A-Fc-YTE is 5.1 days and 24.8 days, respectively. The mice are challenged with intranasal exposure of Omicron B.1.1.529 virus 55 days after a single dose of Nanosota-3A fusions (20 mg kg

Indexed as

Fc engineeringFcRnhalf-life extensionnanobodypharmacokineticspre-exposure prophylaxisSARS-CoV-2 Omicron

Identifiers

PMID40851835
PMCPMC12369981

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.